Literature DB >> 27468195

Umbilical cord-derived mesenchymal stem cells alleviate liver fibrosis in rats.

Ning-Li Chai1, Xiao-Bin Zhang1, Si-Wen Chen1, Ke-Xing Fan1, En-Qiang Linghu1.   

Abstract

AIM: To evaluate the efficacy of umbilical cord-derived mesenchymal stem cells (UC-MSCs) transplantation in the treatment of liver fibrosis.
METHODS: Cultured human UC-MSCs were isolated and transfused into rats with liver fibrosis induced by dimethylnitrosamine (DMN). The effects of UC-MSCs transfusion on liver fibrosis were then evaluated by histopathology; serum interleukin (IL)-4 and IL-10 levels were also measured. Furthermore, Kupffer cells (KCs) in fibrotic livers were isolated and cultured to analyze their phenotype. Moreover, UC-MSCs were co-cultured with KCs in vitro to assess the effects of UC-MSCs on KCs' phenotype, and IL-4 and IL-10 levels were measured in cell culture supernatants. Finally, UC-MSCs and KCs were cultured in the presence of IL-4 antibodies to block the effects of this cytokine, followed by phenotypical analysis of KCs.
RESULTS: UC-MSCs transfused into rats were recruited by the injured liver and alleviated liver fibrosis, increasing serum IL-4 and IL-10 levels. Interestingly, UC-MSCs promoted mobilization of KCs not only in fibrotic livers, but also in vitro. Co-culture of UC-MSCs with KCs resulted in increased production of IL-4 and IL-10. The addition of IL-4 antibodies into the co-culture system resulted in decreased KC mobilization.
CONCLUSION: UC-MSCs could increase IL-4 and promote mobilization of KCs both in vitro and in vivo, subsequently alleviating the liver fibrosis induced by DMN.

Entities:  

Keywords:  DMN; Dimethylnitrosamine; Interleukin-4; Kupffer cells; Liver fibrosis; Mesenchymal stem cells

Mesh:

Substances:

Year:  2016        PMID: 27468195      PMCID: PMC4948270          DOI: 10.3748/wjg.v22.i26.6036

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  46 in total

Review 1.  Mesenchymal stem cells: clinical applications and biological characterization.

Authors:  Frank P Barry; J Mary Murphy
Journal:  Int J Biochem Cell Biol       Date:  2004-04       Impact factor: 5.085

Review 2.  Macrophage plasticity and polarization: in vivo veritas.

Authors:  Antonio Sica; Alberto Mantovani
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

3.  [Spontaneous transformation and immortalization of mesenchymal stem cells in vitro].

Authors:  B V Popov; N S Petrov; V M Mikhaĭlov; A N Tomilin; L L Alekseenko; T M Grinchuk; A M Zaĭchik
Journal:  Tsitologiia       Date:  2009

4.  M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease.

Authors:  Jinghong Wan; Merieme Benkdane; Fatima Teixeira-Clerc; Stéphanie Bonnafous; Alexandre Louvet; Fouad Lafdil; Françoise Pecker; Albert Tran; Philippe Gual; Ariane Mallat; Sophie Lotersztajn; Catherine Pavoine
Journal:  Hepatology       Date:  2013-11-20       Impact factor: 17.425

5.  Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes.

Authors:  Liang Peng; Dong-ying Xie; Bing-Liang Lin; Jing Liu; Hai-peng Zhu; Chan Xie; Yu-bao Zheng; Zhi-liang Gao
Journal:  Hepatology       Date:  2011-07-14       Impact factor: 17.425

6.  Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients.

Authors:  Zheng Zhang; Hu Lin; Ming Shi; Ruonan Xu; Junliang Fu; Jiyun Lv; Liming Chen; Sa Lv; Yuanyuan Li; Shuangjie Yu; Hua Geng; Lei Jin; George K K Lau; Fu-Sheng Wang
Journal:  J Gastroenterol Hepatol       Date:  2012-03       Impact factor: 4.029

Review 7.  Kupffer cells in non-alcoholic fatty liver disease: the emerging view.

Authors:  György Baffy
Journal:  J Hepatol       Date:  2009-03-31       Impact factor: 25.083

8.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

9.  Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice.

Authors:  Claudia Mitchell; Dominique Couton; Jean-Pierre Couty; Marie Anson; Anne-Marie Crain; Vinciane Bizet; Laurent Rénia; Stanislas Pol; Vincent Mallet; Hélène Gilgenkrantz
Journal:  Am J Pathol       Date:  2009-04-09       Impact factor: 4.307

10.  Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis.

Authors:  John T Pesce; Thirumalai R Ramalingam; Margaret M Mentink-Kane; Mark S Wilson; Karim C El Kasmi; Amber M Smith; Robert W Thompson; Allen W Cheever; Peter J Murray; Thomas A Wynn
Journal:  PLoS Pathog       Date:  2009-04-10       Impact factor: 6.823

View more
  14 in total

Review 1.  Progress and prospect of mesenchymal stem cell-based therapy in atherosclerosis.

Authors:  Ximei Zhang; Feng Huang; Yanming Chen; Xiaoxian Qian; Song Guo Zheng
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

Review 2.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

3.  Umbilical Cord-derived Mesenchymal Stem Cells Instruct Monocytes Towards an IL10-producing Phenotype by Secreting IL6 and HGF.

Authors:  Yinan Deng; Yingcai Zhang; Linsen Ye; Tong Zhang; Jintao Cheng; Guihua Chen; Qi Zhang; Yang Yang
Journal:  Sci Rep       Date:  2016-12-05       Impact factor: 4.379

4.  Mesenchymal stem cells rescue acute hepatic failure by polarizing M2 macrophages.

Authors:  Yan-Wei Li; Chong Zhang; Qiu-Ju Sheng; Han Bai; Yang Ding; Xiao-Guang Dou
Journal:  World J Gastroenterol       Date:  2017-12-07       Impact factor: 5.742

Review 5.  Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis.

Authors:  Chenxia Hu; Lingfei Zhao; Jinfeng Duan; Lanjuan Li
Journal:  J Cell Mol Med       Date:  2019-01-11       Impact factor: 5.310

6.  Human amnion mesenchymal stem cells attenuate atherosclerosis by modulating macrophage function to reduce immune response.

Authors:  Xiufang Wei; Guang Sun; Xiaoxue Zhao; Qianqian Wu; Ling Chen; Yichi Xu; Xining Pang; Guoxian Qi
Journal:  Int J Mol Med       Date:  2019-07-23       Impact factor: 4.101

7.  Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/β-catenin pathway.

Authors:  Xiaoli Rong; Junzhi Liu; Xia Yao; Tiechao Jiang; Yimin Wang; Feng Xie
Journal:  Stem Cell Res Ther       Date:  2019-03-18       Impact factor: 6.832

8.  Human umbilical cord-derived mesenchymal stem cells improve the function of liver in rats with acute-on-chronic liver failure via downregulating Notch and Stat1/Stat3 signaling.

Authors:  Yulin He; Xingrong Guo; Tingyu Lan; Jianbo Xia; Jinsong Wang; Bei Li; Chunyan Peng; Yue Chen; Xiang Hu; Zhongji Meng
Journal:  Stem Cell Res Ther       Date:  2021-07-13       Impact factor: 6.832

9.  Intravenous Umbilical Cord-derived Mesenchymal Stem Cells Transplantation Regulates Hyaluronic Acid and Interleukin-10 Secretion Producing Low-grade Liver Fibrosis in Experimental Rat.

Authors:  Taufik Sungkar; Agung Putra; Dharma Lindarto; Rosita Juwita Sembiring
Journal:  Med Arch       Date:  2020-06

10.  Human Umbilical Cord-Derived Mesenchymal Stem Cell Therapy Ameliorates Nonalcoholic Fatty Liver Disease in Obese Type 2 Diabetic Mice.

Authors:  Bing Li; Yu Cheng; Songyan Yu; Li Zang; Yaqi Yin; Jiejie Liu; Lin Zhang; Yiming Mu
Journal:  Stem Cells Int       Date:  2019-11-03       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.